ReviewMedicina (Kaunas, Lithuania)2026
Acute Kidney Injury in Childhood Nephrotic Syndrome: From Hemodynamic Vulnerability and Tubular Stress Toward Biomarker-Guided Management.
Review in Medicina (Kaunas, Lithuania), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) is a clinically important, mechanistically heterogeneous complication of childhood nephrotic syndrome. Similar increases in serum creatinine may reflect reduced effective arterial volume, extracellular volume expansion with pressure-associated dysfunction, acute tubular stress or injury, infection or sepsis, drug toxicity or acute interstitial nephritis, vascular thrombosis, or underlying glomerular disease. These mechanisms often coexist or evolve, so edema and creatinine alone cannot direct therapy. This focused narrative review links the nephrotic substrate and precipitating exposures to predominant or mixed AKI phenotypes, multimodal assessment, and phenotype-guided management. Serum creatinine, urine output, and cystatin C are considered alongside urinary neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and the cellular stress product of tissue inhibitor of metalloproteinases-2 and insulin-like growth factor-binding protein 7 [TIMP-2]·[IGFBP7]. These biomarkers may help distinguish functional filtration loss from tubular stress or damage, but nephrotic-syndrome-specific validation and evidence of therapeutic utility remain limited. Management should integrate serial assessment of perfusion, congestion, fluid balance, urine findings, drug exposures, infection, and vascular or intrinsic kidney disease. Biomarkers are therefore adjuncts, not an established basis for management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.